Identification

Name
Rivaroxaban
Accession Number
DB06228  (DB08477)
Type
Small Molecule
Groups
Approved
Description

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.

Structure
Thumb
Synonyms
Not Available
External IDs
BAY 59-7939 / BAY-59-7939 / JNJ-39039039 / JNJ39039039
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag2008-09-30Not applicableEu
XareltoTablet, film coated20 mgOralBayer Pharma Ag2008-09-30Not applicableEu
XareltoTablet, film coated15 mgOralBayer Pharma Ag2008-09-30Not applicableEu
XareltoTablet10 mgOralBayer2008-09-16Not applicableCanada
XareltoTablet, film coated20 mgOralBayer Pharma Ag2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Pharma Ag2008-09-30Not applicableEu
XareltoTablet, film coated2.5 mgOralBayer Pharma Ag2008-09-30Not applicableEu
XareltoTablet, film coated10 mgOralBayer Pharma Ag2008-09-30Not applicableEu
XareltoKitJanssen Pharmaceuticals2014-09-16Not applicableUs
XareltoTablet, film coated10 mgOralBayer Pharma Ag2008-09-30Not applicableEu
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
XareltoRivaroxaban (15 mg) + Rivaroxaban (20 mg)TabletOralBayer2015-11-02Not applicableCanada
XareltoRivaroxaban (15 mg) + Rivaroxaban (20 mg)TabletOralBayer2015-11-02Not applicableCanada
Categories
UNII
9NDF7JZ4M3
CAS number
366789-02-8
Weight
Average: 435.881
Monoisotopic: 435.065569098
Chemical Formula
C19H18ClN3O5S
InChI Key
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
InChI
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
IUPAC Name
5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide
SMILES
ClC1=CC=C(S1)C(=O)NC[[email protected]]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O

Pharmacology

Indication

Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (<30mL/min).

Structured Indications
Pharmacodynamics

Rivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.

Mechanism of action

Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.

TargetActionsOrganism
ACoagulation factor X
antagonist
Human
Absorption

Following oral administration, rivaroxaban is rapidly absorbed and reaches peak plasma concentration in 2-4 hours. Bioavailability of the 10 mg dose is >80%. However, the 15-20 mg dose have a lower bioavailability if taken in the fasted state and consequently should be taken with food.

Volume of distribution

The steady state Vd is 50 L

Protein binding

Plasma protein binding is about 92% to 95%

Metabolism

Approximately two-thirds of the dose is metabolized. It is metabolized by CYP3A4, CYP3A5, CYP2J2 and CYP-independant mechanisms

Route of elimination

Approximately two-thirds of rivaroxaban is excreted into urine (via active tubular secretion in which approximately 36% as unchanged drug and 30% as inactive metabolism). The remaining third of the administered dose is excreted via feces in which 7% is in the form of unchanged drug and 21% as inactive metabolites.

Half life

The terminal half life is 5-9 hours in adults and 11-13 hours in the elderly.

Clearance

Systemic clearance is approximately 10 L/h, so rivaroxaban is considered a drug with low clearance. Renal clearance is ~3-4 L/h.

Toxicity

Excessive bleeding. Overdosages should be treated using activated charcoal and supportive measures such as mechanical compression and hemodynamic support. If bleeding is not controlled, the following procoagulants can be administered: activated prothrombin complex concentrate, prothrombin complex concentrate and recombinant factor VIIa. There is also a higher chance of post procedural hemorrhage compared to enoxaparin (1.55% vs. 1.39% respectively).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Rivaroxaban.Approved, Investigational
AbciximabAbciximab may increase the anticoagulant activities of Rivaroxaban.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
AcemetacinAcemetacin may increase the anticoagulant activities of Rivaroxaban.Approved
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Rivaroxaban.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Rivaroxaban.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Rivaroxaban.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Rivaroxaban.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Rivaroxaban.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Rivaroxaban.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Rivaroxaban.Approved
AltrenogestThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Rivaroxaban.Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Rivaroxaban.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Rivaroxaban.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Rivaroxaban.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
AmiodaroneThe metabolism of Rivaroxaban can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Rivaroxaban.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Rivaroxaban.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Rivaroxaban.Approved
AncrodAncrod may increase the anticoagulant activities of Rivaroxaban.Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Rivaroxaban.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Rivaroxaban.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Rivaroxaban.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Rivaroxaban.Approved
Antithrombin III humanAntithrombin III human may increase the anticoagulant activities of Rivaroxaban.Approved
ApixabanApixaban may increase the anticoagulant activities of Rivaroxaban.Approved
ApocyninApocynin may increase the anticoagulant activities of Rivaroxaban.Investigational
ApremilastApremilast may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
AprepitantThe serum concentration of Rivaroxaban can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Rivaroxaban.Investigational
AtazanavirThe metabolism of Rivaroxaban can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Rivaroxaban can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Rivaroxaban.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Rivaroxaban.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Rivaroxaban.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Rivaroxaban.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Rivaroxaban.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Rivaroxaban.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Rivaroxaban.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Rivaroxaban.Approved
BeraprostBeraprost may increase the anticoagulant activities of Rivaroxaban.Investigational
BevoniumBevonium may increase the anticoagulant activities of Rivaroxaban.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
BoceprevirThe serum concentration of Rivaroxaban can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Rivaroxaban can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Rivaroxaban can be decreased when it is combined with Bosentan.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Rivaroxaban.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Rivaroxaban.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Rivaroxaban.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Rivaroxaban.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Rivaroxaban.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Rivaroxaban.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Rivaroxaban.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Rivaroxaban.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Rivaroxaban.Approved
CangrelorCangrelor may increase the anticoagulant activities of Rivaroxaban.Approved
CarbamazepineThe metabolism of Rivaroxaban can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Rivaroxaban.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
CeritinibThe serum concentration of Rivaroxaban can be increased when it is combined with Ceritinib.Approved
CertoparinCertoparin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Rivaroxaban.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Rivaroxaban.Approved
CilostazolCilostazol may increase the anticoagulant activities of Rivaroxaban.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Rivaroxaban.Approved, Investigational, Withdrawn
Citric AcidCitric Acid may increase the anticoagulant activities of Rivaroxaban.Approved, Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Rivaroxaban can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Rivaroxaban can be decreased when combined with Clemastine.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Rivaroxaban.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Rivaroxaban.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Rivaroxaban.Approved, Nutraceutical
CloricromenCloricromen may increase the anticoagulant activities of Rivaroxaban.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Rivaroxaban.Experimental
ClotrimazoleThe metabolism of Rivaroxaban can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Rivaroxaban can be decreased when combined with Cobicistat.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Rivaroxaban can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Rivaroxaban.Approved
CrizotinibThe metabolism of Rivaroxaban can be decreased when combined with Crizotinib.Approved
CurcuminCurcumin may increase the anticoagulant activities of Rivaroxaban.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Rivaroxaban.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Rivaroxaban.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the anticoagulant activities of Rivaroxaban.Investigational
Dabigatran etexilateRivaroxaban may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Rivaroxaban can be decreased when it is combined with Dabrafenib.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Rivaroxaban.Experimental
DalteparinDalteparin may increase the anticoagulant activities of Rivaroxaban.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
DarexabanDarexaban may increase the anticoagulant activities of Rivaroxaban.Investigational
DarunavirThe metabolism of Rivaroxaban can be decreased when combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
DeferasiroxThe serum concentration of Rivaroxaban can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Rivaroxaban.Approved
DemegestoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Rivaroxaban.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Rivaroxaban.Approved
DesirudinDesirudin may increase the anticoagulant activities of Rivaroxaban.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Rivaroxaban.Investigational
DesogestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Desogestrel.Approved
DextranDextran may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
Dextran 40Dextran 40 may increase the anticoagulant activities of Rivaroxaban.Approved
Dextran 70Dextran 70 may increase the anticoagulant activities of Rivaroxaban.Approved
Dextran 75Dextran 75 may increase the anticoagulant activities of Rivaroxaban.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Rivaroxaban.Experimental
DiclofenacDiclofenac may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Rivaroxaban.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Rivaroxaban.Approved, Investigational
DienogestThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Rivaroxaban.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Rivaroxaban.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Rivaroxaban.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Rivaroxaban.Approved
DihydroergotamineThe metabolism of Rivaroxaban can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Rivaroxaban.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Rivaroxaban.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Rivaroxaban.Approved
DitazoleDitazole may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Rivaroxaban.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Rivaroxaban.Approved
DoxycyclineThe metabolism of Rivaroxaban can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Rivaroxaban can be decreased when combined with Dronedarone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Rivaroxaban.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Rivaroxaban.Investigational
DydrogesteroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Rivaroxaban.Approved
E-6201E-6201 may increase the anticoagulant activities of Rivaroxaban.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Rivaroxaban.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Rivaroxaban.Approved, Investigational
EnoxaparinEnoxaparin may increase the anticoagulant activities of Rivaroxaban.Approved
EnzalutamideThe serum concentration of Rivaroxaban can be decreased when it is combined with Enzalutamide.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Rivaroxaban.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Rivaroxaban.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Rivaroxaban.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Rivaroxaban.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Rivaroxaban.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Rivaroxaban.Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Rivaroxaban.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Rivaroxaban.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Rivaroxaban.Approved
ErythromycinThe serum concentration of Rivaroxaban can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Rivaroxaban.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Rivaroxaban.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Rivaroxaban.Approved
EstriolEstriol may decrease the anticoagulant activities of Rivaroxaban.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Rivaroxaban.Approved
EstroneEstrone may decrease the anticoagulant activities of Rivaroxaban.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Rivaroxaban.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Rivaroxaban.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Rivaroxaban.Approved
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Rivaroxaban.Withdrawn
EthynodiolThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Rivaroxaban.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
exisulindexisulind may increase the anticoagulant activities of Rivaroxaban.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Rivaroxaban.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Rivaroxaban.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
FentiazacFentiazac may increase the anticoagulant activities of Rivaroxaban.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Rivaroxaban.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Rivaroxaban.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Rivaroxaban.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
FluconazoleThe metabolism of Rivaroxaban can be decreased when combined with Fluconazole.Approved
FluindioneFluindione may increase the anticoagulant activities of Rivaroxaban.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Rivaroxaban.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Rivaroxaban.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
FluvoxamineThe metabolism of Rivaroxaban can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxFondaparinux may increase the anticoagulant activities of Rivaroxaban.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
FosamprenavirThe metabolism of Rivaroxaban can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Rivaroxaban can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Rivaroxaban can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Rivaroxaban can be increased when it is combined with Fusidic Acid.Approved
GabexateGabexate may increase the anticoagulant activities of Rivaroxaban.Investigational
GarlicThe serum concentration of Rivaroxaban can be decreased when it is combined with Garlic.Approved
GenisteinGenistein may decrease the anticoagulant activities of Rivaroxaban.Investigational
GestodeneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Rivaroxaban.Experimental
HeminHemin may increase the anticoagulant activities of Rivaroxaban.Approved
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Rivaroxaban.Experimental
HeparinHeparin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Rivaroxaban.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Rivaroxaban.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Rivaroxaban.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rivaroxaban.Approved
IbudilastIbudilast may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Rivaroxaban.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Rivaroxaban.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Rivaroxaban.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Rivaroxaban.Approved, Nutraceutical
IdelalisibThe serum concentration of Rivaroxaban can be increased when it is combined with Idelalisib.Approved
IdraparinuxIdraparinux may increase the anticoagulant activities of Rivaroxaban.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Rivaroxaban.Investigational
IloprostIloprost may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
ImatinibThe metabolism of Rivaroxaban can be decreased when combined with Imatinib.Approved
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Rivaroxaban.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Rivaroxaban.Approved
IndinavirThe metabolism of Rivaroxaban can be decreased when combined with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Rivaroxaban.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Rivaroxaban.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Rivaroxaban.Experimental
IsavuconazoniumThe metabolism of Rivaroxaban can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Rivaroxaban.Withdrawn
IsradipineThe metabolism of Rivaroxaban can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Rivaroxaban can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Rivaroxaban can be increased when it is combined with Ivacaftor.Approved
KebuzoneKebuzone may increase the anticoagulant activities of Rivaroxaban.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Rivaroxaban.Investigational
KetoconazoleThe metabolism of Rivaroxaban can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Rivaroxaban.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Rivaroxaban.Approved
LetaxabanLetaxaban may increase the anticoagulant activities of Rivaroxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Rivaroxaban.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Rivaroxaban.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Rivaroxaban.Investigational
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Rivaroxaban.Experimental
LonazolacLonazolac may increase the anticoagulant activities of Rivaroxaban.Experimental
LopinavirThe metabolism of Rivaroxaban can be decreased when combined with Lopinavir.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Rivaroxaban.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
LuliconazoleThe serum concentration of Rivaroxaban can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Rivaroxaban can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Rivaroxaban.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Rivaroxaban.Approved
Megestrol acetateThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MelagatranMelagatran may increase the anticoagulant activities of Rivaroxaban.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Rivaroxaban.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Rivaroxaban.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Rivaroxaban.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Rivaroxaban.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Rivaroxaban.Approved
MethylestrenoloneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Methylestrenolone.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Rivaroxaban.Approved, Illicit
MifepristoneThe serum concentration of Rivaroxaban can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Rivaroxaban.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Rivaroxaban.Approved
MitotaneThe serum concentration of Rivaroxaban can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may increase the anticoagulant activities of Rivaroxaban.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Rivaroxaban.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Rivaroxaban.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Rivaroxaban.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Rivaroxaban.Approved
NadroparinNadroparin may increase the anticoagulant activities of Rivaroxaban.Approved
NafamostatNafamostat may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Rivaroxaban.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Rivaroxaban.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Rivaroxaban.Approved, Withdrawn
NelfinavirThe metabolism of Rivaroxaban can be decreased when combined with Nelfinavir.Approved
NepafenacNepafenac may increase the anticoagulant activities of Rivaroxaban.Approved
NetupitantThe serum concentration of Rivaroxaban can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Rivaroxaban can be decreased when it is combined with Nevirapine.Approved
NifenazoneNifenazone may increase the anticoagulant activities of Rivaroxaban.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
NilotinibThe metabolism of Rivaroxaban can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Rivaroxaban.Investigational
NomegestrolThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Rivaroxaban.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Obinutuzumab.Approved
OlaparibThe metabolism of Rivaroxaban can be decreased when combined with Olaparib.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Rivaroxaban.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Rivaroxaban.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Rivaroxaban.Approved, Nutraceutical
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Rivaroxaban.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Rivaroxaban.Vet Approved
OsimertinibThe serum concentration of Rivaroxaban can be increased when it is combined with Osimertinib.Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Rivaroxaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Rivaroxaban.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Rivaroxaban.Investigational
PalbociclibThe serum concentration of Rivaroxaban can be increased when it is combined with Palbociclib.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Rivaroxaban.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Rivaroxaban.Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Rivaroxaban.Approved
PentobarbitalThe serum concentration of Rivaroxaban can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Rivaroxaban.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PethidineThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Pethidine.Approved
PhenindionePhenindione may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PhenobarbitalThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
PhenytoinThe serum concentration of Rivaroxaban can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Rivaroxaban.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Rivaroxaban.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Rivaroxaban.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Rivaroxaban.Approved
PosaconazoleThe metabolism of Rivaroxaban can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Rivaroxaban.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Rivaroxaban.Approved
PrimidoneThe serum concentration of Rivaroxaban can be decreased when it is combined with Primidone.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Rivaroxaban.Experimental
PromegestoneThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Rivaroxaban.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Rivaroxaban.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Rivaroxaban.Experimental
Protein CProtein C may increase the anticoagulant activities of Rivaroxaban.Approved
Protein S humanProtein S human may increase the anticoagulant activities of Rivaroxaban.Approved
ProtocatechualdehydeProtocatechualdehyde may increase the anticoagulant activities of Rivaroxaban.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Rivaroxaban.Approved
PTC299PTC299 may increase the anticoagulant activities of Rivaroxaban.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Rivaroxaban.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Rivaroxaban.Investigational
RanolazineThe serum concentration of Rivaroxaban can be increased when it is combined with Ranolazine.Approved, Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Rivaroxaban.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Rivaroxaban.Approved
ReviparinReviparin may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
RibociclibThe serum concentration of Rivaroxaban can be increased when it is combined with Ribociclib.Approved
RidogrelRidogrel may increase the anticoagulant activities of Rivaroxaban.Approved
RifabutinThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Rivaroxaban can be decreased when it is combined with Rifapentine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Rivaroxaban.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Rivaroxaban.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Rivaroxaban.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Rivaroxaban.Approved
SaquinavirThe metabolism of Rivaroxaban can be decreased when combined with Saquinavir.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Rivaroxaban.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Rivaroxaban.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Rivaroxaban.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Rivaroxaban.Approved
SemapimodSemapimod may increase the anticoagulant activities of Rivaroxaban.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Rivaroxaban.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Rivaroxaban.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Rivaroxaban.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Rivaroxaban.Approved, Investigational
SiltuximabThe serum concentration of Rivaroxaban can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Rivaroxaban can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Rivaroxaban.Approved
SRT501SRT501 may increase the anticoagulant activities of Rivaroxaban.Investigational
St. John's WortThe serum concentration of Rivaroxaban can be decreased when it is combined with St. John&#39;s Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Rivaroxaban can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Rivaroxaban.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Rivaroxaban.Approved
SulfisoxazoleThe metabolism of Rivaroxaban can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Rivaroxaban.Approved
SulodexideSulodexide may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Rivaroxaban.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Rivaroxaban.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Rivaroxaban.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Rivaroxaban.Approved, Investigational
TarenflurbilTarenflurbil may increase the anticoagulant activities of Rivaroxaban.Investigational
TelaprevirThe metabolism of Rivaroxaban can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Rivaroxaban can be decreased when combined with Telithromycin.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Rivaroxaban.Approved
TenidapTenidap may increase the anticoagulant activities of Rivaroxaban.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Rivaroxaban.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Rivaroxaban.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Rivaroxaban.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Rivaroxaban.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Rivaroxaban.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Rivaroxaban.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Rivaroxaban.Approved
TiboloneTibolone may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Rivaroxaban.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Rivaroxaban.Approved
TinoridineTinoridine may increase the anticoagulant activities of Rivaroxaban.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Rivaroxaban.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Rivaroxaban.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Rivaroxaban.Approved
TocilizumabThe serum concentration of Rivaroxaban can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
TolmetinTolmetin may increase the anticoagulant activities of Rivaroxaban.Approved
TositumomabThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Rivaroxaban.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Rivaroxaban.Approved
TribenosideTribenoside may increase the anticoagulant activities of Rivaroxaban.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Rivaroxaban.Approved
TriptolideTriptolide may increase the anticoagulant activities of Rivaroxaban.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Rivaroxaban.Approved
TroxerutinTroxerutin may increase the anticoagulant activities of Rivaroxaban.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Rivaroxaban.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Rivaroxaban.Approved, Investigational
VenlafaxineThe metabolism of Rivaroxaban can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Rivaroxaban.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Rivaroxaban.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Rivaroxaban.Approved
VoriconazoleThe metabolism of Rivaroxaban can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinWarfarin may increase the anticoagulant activities of Rivaroxaban.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Rivaroxaban.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Rivaroxaban.Approved
ZileutonZileuton may increase the anticoagulant activities of Rivaroxaban.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Rivaroxaban can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Rivaroxaban.Withdrawn
Food Interactions
  • Food should be taken with the 15 mg and 20 mg tablet. Food increases the bioavailability of the 20 mg dose.
  • Foods with antiplatelet/anticoagulants properties such as horseradish, gingko, ginger, garlic, feverfew
  • St. John's Wort is a CYP3A4 inducer and will decrease levels of rivaroxaban

References

Synthesis Reference

Prabhudas BODHURI, Gamini Weeratunga, "PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF." U.S. Patent US20100273790, issued October 28, 2010.

US20100273790
General References
  1. Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM: Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . [PubMed:18491993]
  2. Alban S: Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des. 2008;14(12):1152-75. [PubMed:18473863]
  3. Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E: Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. [PubMed:19846028]
  4. Imberti D, Dall'Asta C, Pierfranceschi MG: Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009 Dec;4(6):471-7. doi: 10.1007/s11739-009-0293-9. [PubMed:19696978]
  5. Alexander D, Jeremias A: Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opin Investig Drugs. 2011 Jun;20(6):849-57. doi: 10.1517/13543784.2011.580274. Epub 2011 May 10. [PubMed:21554163]
  6. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472]
External Links
KEGG Drug
D07086
PubChem Compound
9875401
PubChem Substance
175427064
ChemSpider
8051086
BindingDB
7840
ChEBI
68579
ChEMBL
CHEMBL198362
HET
RIV
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Rivaroxaban
ATC Codes
B01AF01 — Rivaroxaban
AHFS Codes
  • 20:12.04.92 — Miscellaneous Anticoagulants
PDB Entries
2w26
FDA label
Download (537 KB)
MSDS
Download (480 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailablePediatrics / Thrombosis, Venous1
1CompletedNot AvailablePharmacokinetics1
1CompletedNot AvailableTherapeutic Equivalency1
1CompletedNot AvailableThrombosis, Venous1
1CompletedOtherBiological Availability1
1CompletedOtherHealthy Volunteers1
1CompletedPreventionProphylaxis of Venous Thromboembolism2
1CompletedTreatmentBioavailability / Healthy Participants / Pharmacokinetics1
1CompletedTreatmentEmbolism, Atrial Fibrillation and Venous Thrombosis2
1CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
1CompletedTreatmentHaemorrhage1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHealthy Volunteers / Impaired Renal Function1
1CompletedTreatmentThrombosis1
1RecruitingOtherThrombosis1
1TerminatedTreatmentGastric Bypass Status1
1, 2RecruitingOtherThromboembolism1
1, 2RecruitingPreventionNeoplasms1
2CompletedPreventionCardiovascular Disease, Coronary Artery Disease1
2CompletedPreventionNonvalvular Atrial Fibrillation3
2CompletedPreventionPrevention / Thromboembolism1
2CompletedPreventionProphylaxis of Venous Thromboembolic Events1
2CompletedPreventionVenous Thromboembolism4
2CompletedTreatmentAcute Coronary Syndromes (ACS)2
2CompletedTreatmentDeep Vein Thrombosis (DVT) / Thrombosis, Venous2
2CompletedTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)1
2CompletedTreatmentThrombosis, Venous1
2CompletedTreatmentVenous Thromboembolism2
2Enrolling by InvitationTreatmentSickle Cell Disorders / Sickle Cell-Beta0-Thalassemia / Sickle Cell-beta^0^-Thalassemia1
2Not Yet RecruitingTreatmentCerebral Venous Thrombosis1
2RecruitingTreatmentCancer-associated Thrombosis / Duodenal Cancer / Esophageal Cancers / Hepatobiliary Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
2RecruitingTreatmentHaemorrhage1
2RecruitingTreatmentValvular Heart Disease1
2TerminatedTreatmentAnticoagulants / Aortic Valve Disorder / Heart Valve Prosthesis Implantation1
2Unknown StatusPreventionHaemorrhage / Venous Thromboembolism1
2, 3RecruitingTreatmentMenstruation / Venous Thromboembolism1
2, 3Unknown StatusTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)1
3Active Not RecruitingPreventionPrevention & Control1
3Active Not RecruitingPreventionVenous Thromboembolism1
3Active Not RecruitingTreatmentAntiphospholipid Syndrome1
3CompletedPreventionArthritis / Knee Osteoarthritis (Knee OA) / Osteoarthritis, Hip / Thromboembolism1
3CompletedPreventionNonvalvular Atrial Fibrillation2
3CompletedPreventionNonvalvular Atrial Fibrillation / Strokes / Systemic Embolism1
3CompletedPreventionPrevention / Venous Thromboembolism1
3CompletedPreventionProphylaxis of Pulmonary embolism / Thromboembolism / Thrombosis / Thrombosis, Venous / Venous Thromboembolism1
3CompletedPreventionVenous Thromboembolism5
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Myocardial Infarction (MI) / Myocardial Ischemia / Unstable Angina (UA)1
3CompletedTreatmentDeep Vein Thrombosis (DVT)1
3CompletedTreatmentNonvalvular Atrial Fibrillation2
3CompletedTreatmentNonvalvular Atrial Fibrillation / Percutaneous Coronary Intervention1
3CompletedTreatmentPrevention / Venous Thromboembolism1
3CompletedTreatmentSuperficial Vein Thrombosis1
3CompletedTreatmentThrombosis, Venous1
3CompletedTreatmentVenous Thromboembolism1
3CompletedTreatmentProphylaxis of Pulmonary embolism2
3Not Yet RecruitingPreventionAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
3Not Yet RecruitingPreventionAtrial Flutter / Intracranial Hemorrhage, Hypertensive / Intracranial Hemorrhages / Intraventricular Hemorrhage / Microhaemorrhage / Nonvalvular Atrial Fibrillation / Small Vessel Cerebrovascular Disease / Subarachnoid Hemorrhage / Subdural haematoma1
3Not Yet RecruitingPreventionRheumatic Heart Disease2
3Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
3Not Yet RecruitingTreatmentVenous Thromboembolism1
3RecruitingDiagnosticAortic Valve Stenosis / Cardiovascular Disease (CVD) / Heart Valve Diseases / Thrombosis / Ventricular Outflow Obstruction1
3RecruitingPreventionCancers / Neoplasms1
3RecruitingPreventionHeart Failure, Unspecified / Infectious Diseases / Respiratory Insufficiency / Rheumatic Diseases / Stroke Acute1
3RecruitingPreventionNon-major Orthopaedic Surgery1
3RecruitingPreventionNonvalvular Atrial Fibrillation1
3RecruitingPreventionPeripheral Artery Disease (PAD)1
3RecruitingPreventionPrevention of Venous Thromboembolism1
3RecruitingPreventionThrombosis1
3RecruitingPreventionTranscatheter Aortic Valve Replacement1
3RecruitingTreatmentAntiphospholipid Syndrome1
3RecruitingTreatmentCancers / Venous Thromboembolism1
3RecruitingTreatmentChronic Portal Vein Thrombosis / Deep Vein Thrombosis (DVT)1
3RecruitingTreatmentCoronary Artery Disease / Heart Failure, Unspecified1
3RecruitingTreatmentDeep Vein Thrombosis (DVT)1
3RecruitingTreatmentDeep Venous Thrombosis1
3RecruitingTreatmentHematoma1
3RecruitingTreatmentImpaired Renal Function1
3RecruitingTreatmentLiver Cirrhosis1
3RecruitingTreatmentMesenteric Vein Thrombosis / Portal Vein Thrombosis / Splenic Vein Thrombosis1
3RecruitingTreatmentNeoplasms / Venous Thromboembolism1
3RecruitingTreatmentPortal Vein Thrombosis1
3RecruitingTreatmentSymptomatic Superficial Vein Thrombosis1
3RecruitingTreatmentType 2 Diabetic Patients1
3RecruitingTreatmentVenous Thromboembolism1
3TerminatedPreventionStrokes1
3TerminatedTreatmentCardiac surgery, heparin-induced thrombocytopenia and thrombosis syndrome1
3Unknown StatusPreventionVenous Thromboembolism1
4Active Not RecruitingTreatmentVenous Thromboembolism1
4Active Not RecruitingTreatmentProphylaxis of Pulmonary embolism1
4CompletedBasic ScienceAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
4CompletedBasic ScienceVenous Thromboembolism1
4CompletedOtherAntiphospholipid Antibody Syndrome1
4CompletedPreventionFemur Head Necrosis / Fracture of Neck of Femur / Osteoarthritis, Hip1
4CompletedPreventionKnee Osteoarthritis (Knee OA)1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedTreatmentCancer-associated Thrombosis / Haemorrhage / Recurrences / Rivaroxaban1
4CompletedTreatmentCentral Venous Catheter Thrombosis / Neoplasms1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentHaemorrhage / Nonvalvular Atrial Fibrillation / Strokes / Thrombo-embolism1
4Not Yet RecruitingPreventionKnee Osteoarthritis (Knee OA)2
4Not Yet RecruitingPreventionNonvalvular Atrial Fibrillation / Strokes1
4Not Yet RecruitingSupportive CareProphylaxis of Pulmonary embolism / Thrombosis, Venous1
4Not Yet RecruitingTreatmentVenous Thromboembolism1
4RecruitingBasic ScienceAtrial Fibrillation or Pulmonary Embolism / Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location / Need of Long Term Oral Anticoagulation Therapy (OAT)1
4RecruitingOtherNonvalvular Atrial Fibrillation1
4RecruitingPreventionAortic Valve Insufficiency / Aortic Valve Stenosis / Thrombosis1
4RecruitingPreventionAtherosclerosis1
4RecruitingPreventionCalcifications, Vascular1
4RecruitingPreventionNonvalvular Atrial Fibrillation1
4RecruitingPreventionNonvalvular Atrial Fibrillation / Strokes1
4RecruitingTreatmentAnticoagulating Treatment on a Duration at Least 12-month-old Superior / Anticoagulation Treatment at Least > or = to 12-month / Permanent Atrial Fibrillation / Prophylaxis of Pulmonary embolism / Thrombosis, Venous1
4RecruitingTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism1
4RecruitingTreatmentDiabetes1
4RecruitingTreatmentNonvalvular Atrial Fibrillation3
4TerminatedTreatmentProphylaxis of Pulmonary embolism / Thrombosis, Venous1
4Unknown StatusNot AvailableAnticoagulant Overdosage / Anticoagulant-induced Bleeding / Hemorrhage / Thrombosis1
4Unknown StatusTreatmentNonvalvular Atrial Fibrillation1
4WithdrawnTreatmentComplications; Arthroplasty1
4WithdrawnTreatmentCoronary Heart Disease (CHD) / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Elevation Myocardial Infarction (STEMI) / Stable Angina (SA) / Unstable Angina (UA)1
Not AvailableActive Not RecruitingNot AvailableAnticoagulation1
Not AvailableActive Not RecruitingNot AvailableIschemia, Brain2
Not AvailableActive Not RecruitingNot AvailableNonvalvular Atrial Fibrillation3
Not AvailableActive Not RecruitingNot AvailableStroke, Ischemic1
Not AvailableActive Not RecruitingNot AvailableStrokes1
Not AvailableActive Not RecruitingNot AvailableVenous Thromboembolism1
Not AvailableActive Not RecruitingSupportive CareNon-valvular Atrial Fibrillation (NVAF)1
Not AvailableAvailableNot AvailableThromboembolism1
Not AvailableCompletedNot AvailableArthroplasty, Replacement, Hip / Arthroplasty, Replacement, Knee1
Not AvailableCompletedNot AvailableAtrial Fibrillation (Prevention of Stroke)1
Not AvailableCompletedNot AvailableBlood Clots1
Not AvailableCompletedNot AvailableDeep Vein Thrombosis (DVT) / Thrombosis, Venous1
Not AvailableCompletedNot AvailableMajor Bleeding / Venous Thromboembolism1
Not AvailableCompletedNot AvailableNonvalvular Atrial Fibrillation14
Not AvailableCompletedNot AvailableThrombosis, Venous2
Not AvailableCompletedNot AvailableVenous Thromboembolism3
Not AvailableCompletedTreatmentPortal Vein Thrombosis1
Not AvailableNot Yet RecruitingNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableNot Yet RecruitingNot AvailableSpinal Cord Injuries (SCI) / Thromboembolism1
Not AvailableNot Yet RecruitingTreatmentAcute Exacerbation Copd / Venous Thromboembolism1
Not AvailableRecruitingNot AvailableAcute Coronary Syndromes (ACS)1
Not AvailableRecruitingNot AvailableAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation / Prophylaxis of Pulmonary embolism / Thrombosis, Venous2
Not AvailableRecruitingNot AvailableAnticoagulants and Bleeding Disorders / Venous Thromboembolism1
Not AvailableRecruitingNot AvailableNonvalvular Atrial Fibrillation2
Not AvailableRecruitingNot AvailableStrokes1
Not AvailableRecruitingNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableRecruitingNot AvailableVenous Thromboembolism1
Not AvailableRecruitingNot AvailableVenous Thrombosis and Pulmonary Embolism1
Not AvailableRecruitingNot AvailableProphylaxis of Pulmonary embolism1
Not AvailableRecruitingSupportive CareHemorrhage / Nonvalvular Atrial Fibrillation / Periodontal Diseases1
Not AvailableRecruitingTreatmentBlood Clots / Cancers / Deep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
Not AvailableRecruitingTreatmentDeep Venous Thrombosis1
Not AvailableUnknown StatusSupportive CareBlood Loss / Osteoarthritis, Hip1
Not AvailableUnknown StatusTreatmentIleofemoral Deep Vein Thrombosis1
Not AvailableWithdrawnNot AvailableKnee Replacement Surgery / Prophylaxis, Thromboembolism, Venous / Total Hip Replacement1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit
TabletOral
TabletOral10 mg
TabletOral15 mg
TabletOral20 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral10 mg
Tablet, film coatedOral15 mg
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral2.5 mg
Tablet, film coatedOral20 mg
Tablet, film coatedOral20 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2396561No2008-10-142020-12-11Canada
CA2547113No2012-01-242024-11-13Canada
US7157456No2001-02-082021-02-08Us
US7585860No2000-12-112020-12-11Us
US7592339No2000-12-112020-12-11Us
US9539218No2014-02-172034-02-17Us
US9415053No2004-11-132024-11-13Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP1.74ALOGPS
logP1.9ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area88.18 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.74 m3·mol-1ChemAxon
Polarizability43.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9462
Caco-2 permeable+0.6822
P-glycoprotein substrateNon-substrate0.5691
P-glycoprotein inhibitor IInhibitor0.6325
P-glycoprotein inhibitor IIInhibitor0.5601
Renal organic cation transporterNon-inhibitor0.7562
CYP450 2C9 substrateNon-substrate0.7866
CYP450 2D6 substrateNon-substrate0.8761
CYP450 3A4 substrateSubstrate0.5964
CYP450 1A2 substrateNon-inhibitor0.6469
CYP450 2C9 inhibitorNon-inhibitor0.7035
CYP450 2D6 inhibitorNon-inhibitor0.7516
CYP450 2C19 inhibitorInhibitor0.6475
CYP450 3A4 inhibitorNon-inhibitor0.6667
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7463
Ames testNon AMES toxic0.6162
CarcinogenicityNon-carcinogens0.8838
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.4353 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8938
hERG inhibition (predictor II)Inhibitor0.6205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Phenylmorpholines
Alternative Parents
Thiophene carboxamides / 2-heteroaryl carboxamides / 2,5-disubstituted thiophenes / Oxazolidinones / Aryl chlorides / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Carbamate esters / Heteroaromatic compounds / Secondary carboxylic acid amides
show 11 more
Substituents
Phenylmorpholine / 2-heteroaryl carboxamide / Thiophene carboxamide / Thiophene carboxylic acid or derivatives / 2,5-disubstituted thiophene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Oxazolidinone / Benzenoid
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid amide, organochlorine compound, thiophenes, lactam, aromatic amide, morpholines, oxazolidinone (CHEBI:68579)

Targets

Details
1. Coagulation factor X
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI: Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010 Jun;44(6):1061-71. doi: 10.1345/aph.1M681. Epub 2010 Apr 27. [PubMed:20424181]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Mismetti P, Laporte S: [Rivaroxaban: clinical pharmacology]. Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S16-21. doi: 10.1016/S0750-7658(08)75142-6. [PubMed:19185782]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible f...
Gene Name
CYP2J2
Uniprot ID
P51589
Uniprot Name
Cytochrome P450 2J2
Molecular Weight
57610.165 Da
References
  1. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [PubMed:20135071]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [PubMed:23645472]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Walenga JM, Adiguzel C: Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010 Jun;64(7):956-67. doi: 10.1111/j.1742-1241.2009.02286.x. [PubMed:20584229]
  2. Chen T, Lam S: Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism. Cardiol Rev. 2009 Jul-Aug;17(4):192-7. doi: 10.1097/CRD.0b013e3181aa2154. [PubMed:19525681]

Drug created on March 19, 2008 10:18 / Updated on November 22, 2017 12:36